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Background: Chronic myeloid leukemia is a clonal myeloproliferative disorder disease in which BCR/ABL plays an
important role as an oncoprotein and molecular target. Despite the success of targeted therapy using tyrosine
kinase inhibitors, CML remains largely incurable, most likely due to the treatment resistance after firstly chemical
therapy. So know well the unique molecular pathway of CML is very important.
Methods: The expressions of CD44 in different leukemia patients and cell lines were detected by real-time PCR and
western blotting. The effects of CD44 on proliferation of K562 cells were determined using the MTT and colony
formation assays, and even in a nude mouse transplantation model. Then, the cell cycle changes were detected by
flow cytometric analysis and the early apoptosis of cells was detected by the annexin V/propidium iodide double-
staining assay. The expressions of the cycles and apoptosis-related proteins p21, Cyclin D1 and Bcl-2 were analyzed
by western blot and real-time PCR assay. Finally, the decreased nuclear accumulation of β-catenin was detected by
western blotting and immunefluorescence.
Results: Firstly, we showed that CD44 expression was increased in several kinds of leukemia patients and K562
cells. By contrast, the down-regulation of CD44 resulted in decreased proliferation with a G0/G1 arrest of cell cycle
in K562 cells according to the MTT assay and the flow cytometric analysis. And no significant induction of both the
early and late phases of apoptosis was shown by the annexin V-FITC and PI staining. During this process, p21 and
cyclin D1 are the major causes for cell cycle arrest. In addition, we found CD44 down-regulation decreased the
expression of β-catenin and increased the expression of phosphorylated β-catenin. The instability of Wnt/β-catenin
pathway induced by increased expression of p-β-catenin resulted in a decreased nuclear accumulation in CD44
silenced K562 cells. In the nude mouse transplantation model, we also found the same results.
Conclusions: These results show that K562 cells depend to a greater extent on CD44 for proliferation, and CD44
down-regulation may induce a cell cycle arrest through Wnt/β-catenin pathway. CD44 blockade may be beneficial
in therapy of CML.
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Chronic myeloid leukemia (CML), characterized by
granulocytosis and splenomegaly, is a myeloproliferative
disease and the disease course of CML is triphasic, start-
ing with a chronic phase, progressing to an accelerated
phase and ultimately ending in a terminal phase called
blast crisis [1]. BCR/ABL is derived from chromosomal* Correspondence: pang@ihcams.ac.cn
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from chromosome 9 to the portion of BCR gene locus
on chromosome 22 t (9;22)), yielding the Philadelphia
(Ph) chromosome that is present in over 90% of CML
[2,3]. The Philadelphia chromosome in CML gives rise
to constitutively active protein tyrosine kinase product
BCR-ABL, which is important because in patients with
CML, there is clonal expansion of hematopoietic cells
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eration of leukemic cells in mouse models of CML [4,5].
Inhibition of BCR-ABL with kinase inhibitors such as
imatinib mesylate in the treatment of Ph+ CML is the
current standard therapy, but it is highly effective in
controlling but not curing the disease. This is largely
due to the inability of these kinase inhibitors to kill
leukemia stem cells (LSCs) responsible for disease re-
lapse [2]. This ‘native’ resistance of LSCs in CML to
imatinib and other kinase inhibitors suggests that the
kinase somehow turns on unique molecular pathways in
LSCs through both kinase-dependent and, more import-
antly, kinase-independent mechanisms [6].
To resolve the matter related to the drug resistance of
LSCs in CML, it is essential to fully understand the mo-
lecular mechanisms in both kinase-dependent and kinase-
independent pathways in CML. It is particularly crucial to
identify the key genes that have significant roles in their
survival and self-renewal. Emerging studies show that
CD44 is an important biomarker of a cellular subpopula-
tion (cancer stem cells, CSCs), which are capable of self-
renewal and have the capacity for initiation, progression,
invasion, metastasis, tumor recurrence, and resistance to
chemo- and radiotherapy [7]. CD44 denotes a large family
of transmembrane glycoproteins that are expressed in a
variety of cells and tissues and plays a critical role in a var-
iety of cellular behaviors, including adhesion, migration,
invasion, and survival [8]. Daniela et al. also found CD44
was indispensable for BCR-ABL-expressing leukemic stem
cell to initiate CML and CD44 blockade decreased en-
graftment and impaired induction of CML-like myelopro-
liferative disease [9].
The other key signal is Wnt/β-catenin, which are secreted
signaling molecules that influence both development and
cancer. Wnt/β-catenin regulates the differentiation of limbs,
brain, kidney, and the reproductive tract in mice [10,11]. In
addition to its importance in normal development, dysregu-
lation of the Wnt/β-catenin pathway has potent oncogenic
effects. Mutations in APC as well as β-catenin, a key medi-
ator of Wnt/β-catenin signaling, are also found in a major-
ity of sporadic colon cancers, hepatocellular carcinoma, as
well as thyroid cancer, and ovarian cancer [12]. The fact is
that Wnt/β-catenin signaling is dysregulated in multiple
solid cancers together with its observed influence on
hematopoietic stem and progenitor cells [13-16]. In blas-
tcrisis CML patients, β-catenin is activated in myeloid pro-
genitors and the activated β-catenin translocates to the
nucleus [4], where it interacts with lymphoid enhancer/
T-cell transcription factors and regulates the expression
of genes. Also, β-catenin has been shown to be involved
in BCR-ABL leukemogenesis. BCR-ABL stabilizes β-
catenin in myeloid cells through induction of tyrosine
phosphorylation and activation of β-catenin in BCR-
ABL-positive granulocyte-macrophage progenitors fromblastic phase CML patients facilitates the acquisition by
these cells of properties of LSCs [1].
In this study, we used K562 chronic myeloid leukemia
cells in vitro and in vivo to provide further evidence that
CD44 and its target- β-catenin are essential for survival
and self-renewal of CML cells.
Results
Expression of CD44 in leukemia
We first compared CD44 expression of patients with dif-
ferent leukemias by PCR and real-time PCR. We chose 4
acute myeloid leukaemia (AML) patients, 4 chronic
myeloid leukemia (CML) patients, 4 acute lymphoblastic
leukemia (ALL) patients, 3 myeloproliferative neoplasm
(MPN) patients, 3 polycythemia vera (PV) patients, 2 es-
sential thrombocythemia (ET) patients and 2 healthy
volunteers to evaluate the expressions of CD44. The
real-time PCR analysis revealed that the expressions of
CD44 in leukemia patients were higher than that in
healthy subjects, although the degrees of discrepancy
were different (Figure 1A and B). Then we respectively
chose one patient from each kind of diseases to compare
the protein expression of CD44 between leukemia pa-
tients and healthy volunteers. Although the protein results
of western blotting were little different from the RT-PCR
results, all protein expressions of CD44 in patients were
higher than that in normal controls (Figure 1C and D).
And we also detected the expression of CD44 in K562
chronic myeloid leukemia cells. Compared with CD44 ex-
pression in two healthy volunteers, CD44 level in K562
cells was higher by nearly 3 fold (Figure 1E). Results of
western blotting also showed the distinctive signals for
the bands of CD44 in these samples. The results
showed the protein expression of CD44 in K562 cells
was higher, similar to our previous findings in mRNA
(Figure 1F and G). These data indicate that the expres-
sion of CD44 in leukemia patients is higher than that in
healthy volunteers.
CD44 down-regulation inhibits the proliferation
of K562 cells
According to the above results, the level of CD44 ex-
pression may be associated with aggressive tumor cells
behaviors. So, to confirm the function of CD44 on pro-
liferation, three CD44 shRNA plasmids were constructed
and transfected into K562 cells, which express a higher
level of CD44 and exhibit a more proliferative pheno-
type. After transfection, CD44 expression in K562 cells
markedly decreased compared with control. In addition,
the shRNA1 and 2 plasmids were more effective in de-
creasing the expression of CD44 (Figure 2A and B). As a
membrane-type protein, the expression of CD44 on the
membranes of K562 cells after transfection was detected
by confocal laser microscope. The results showed that
Figure 1 Expression of CD44 in patients’ samples and leukemic cells. (A/B) Expression patterns of CD44 in leukemic patients’ samples were
analyzed by PCR and real-time quantitative PCR analysis. PCR reactions were performed on templates of cDNA from different patients’ cells using a set
of primers as in Materials and methods. (C) The protein expressions of CD44 in different patients were analyzed by western blotting. (D) The relative
protein expression of CD44 compared to GAPDH. (E) Real-time quantitative PCR analysis of CD44 gene expression in normal volunteers and K562 cells.
(F) The protein expressions of CD44 in normal controls and K562 cells. (G) The relative protein expression of CD44 compared to GAPDH. For real-time
quantitative PCR and western blotting, GAPDH was used as an internal control. *, P < 0.05, **, P < 0.01, compared with the control.
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cantly decreased as the results of western blotting, and
the ring forms of CD44 expression around the mem-
brane of K562 cells were broken and some of them
even disappeared (Figure 2C). We also tested the
membrane-type CD44 expression by using flow cytom-
etry and the results showed that the membrane-type
CD44 expression was down-regualted compared to the
control (Figure 2E). Down-regulation of CD44 in K562
cells resulted in a dramatic change of proliferation. We
performed the nonradioactive quantification of cell
proliferation and cell viability (3-[4,5-dimethylthiazol-
2-yl]-2,5- diphenyl tetrazolium bromide (MTT) assay)
for investigating the proliferation state of K562 cells.
The result of MTT assay showed that when the expres-
sion of CD44 in K562 was down-regulated, the prolifer-
ation of K562 cells was significantly decreased. This
decreased proliferation of these myeloid cells also cor-
related with decreased CD44 expression (Figure 2D).CD44 down-regulation induces a G0/G1 arrest in K562 cells
Cell cycle arrest is a common feature of cells undergoing
terminal differentiation and defective proliferation.
Based on the growth inhibitory effects of CD44 down-
regulation on myeloid leukemia cell lines, we investi-
gated their cell cycle progression of CD44 silencing
K562 cells. The DNA contents of K562 cells after trans-
fection were analyzed by FACS. Surprisingly, we ob-
served a change in cell cycle of K562 cells when CD44
expression was inhibited compared to both K562 cells
and cells treated with scramble plasmids. The results
showed that CD44 knockdown K562 cells underwent a
G0/G1 arrest. The proportion of cells in G0/G1 phase in-
creased from 21% (controls) to 32% in CD44 silencing
K562 cells (Figure 3A). This was mirrored by a decrease
in the proportion of cells in the S and G2 phase from
56% (controls) to 53% in CD44 silencing K562 cells and
from 21% (controls) to 14% in CD44 silencing K562 cells
respectively (Figure 3A and C).
Figure 2 Decreased proliferation in K562 cells upon CD44 silencing. (A/B) Down-regulation of CD44 mRNA/protein expression in K562 cells
after CD44 interference. (C) Confocal laser microscope showing localization of CD44 in K562 cells after transfection. The green panel is GFP;
the red panel is CD44 and the blue panel is cell nuclear. (D) Effect of CD44 shRNA on the proliferation of K562 cells as assessed by MTT assay.
(E) CD44 surface expression detected by flow cytometry. CD44 (red), isotype control (green). Results are shown as mean ± SD of three independ-
ent experiments, each experiment in triplicate. *, P < 0.05, **, P < 0.01, compared with the control.
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to cell death, the levels of apoptosis were measured in
K562 cells with reduced CD44 levels by flow cytometry.
The percentage of APC-Annexin V single positive cells
was not significantly different compared to control cells,indicating that the reduced cell proliferation was not
due to cell death (Figure 3B and D). These data suggest
that the growth inhibitory effect of CD44 suppression on
K562 chronic myeloid cells is, in part, due to its effect
on cell cycle arrest progression.
Figure 3 CD44 down-regulation arrests K562 cells in the G1 phase of cell cycle. (A) Cell cycle distribution of K562 cells before and after
transfecting with CD44 shRNA. At the figures, cells were washed with PBS, and stained for DNA with propidium iodide as described in Materials
and methods. Cell cycle distribution was then determined by FACS analysis. (B) Cell death distribution of K562 cells after treatment with CD44
shRNA. At the figures, cells were washed with PBS, and stained with APC-Annexin V and propidium iodide as described in Materials and methods.
Cell death distribution was then determined by FACS analysis. (C) The relative distribution of cell cycle of K562 cells after transfection. (D) The
relative distribution of cell death of K562 cells after transfection.
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down-regulates the expression of cyclin D1
Based on the effects of CD44 on G1 phase accumulation,
we hypothesized the role of major G1 regulatory pro-
teins. We examined the effect of CD44 shRNA on p21
protein expression. Our results show that CD44 shRNAtreatment to K562 cells caused marked up-regulation of
p21 protein expression (Figure 4A-C). Interestingly, in-
creased p21 stability could account for the defects in prolif-
eration and G1 arrest. P21 was discovered as a component
of a quaternary complex consisting of cyclin D1, a CDK,
the proliferating cell nuclear antigen (PCNA), and p21. So
Figure 4 CD44 down-regulation induces the expression of p21 and down-regulates the expression of major cell cycle regulatory
protein-cyclin D1. (A/B) Increased p21 mRNA/protein expression in CD44 silenced K562 cells. (C) The relative protein expression of p21
compared to GAPDH. (D/E) Decreased cyclin D1 mRNA/protein expression in K562 cells after CD44 interference. (F) The relative protein
expression of cyclin D1 compared to GAPDH. (G/H) Unchanged protein expression of Bcl-xl. For real-time quantitative PCR and western blotting,
GAPDH was used as an internal control. *, P < 0.05, **, P < 0.01, compared with the control.
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cing K562 cells. The results of western blotting showed
that the protein expression of cyclin D1 was significantly
decreased by CD44 down-regulation (Figure 4D-F), and
this inhibition of cyclin D1 was correlated with increasedlevel of p21. We also investigated the expression of anti-
apoptotic protein Bcl-xl to verify the results of cells
death assay. And the results of western blotting showed
that the expression of Bcl-xl was not significantly chan-
ged (Figure 4G-H). These data suggest that induction
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may be mediated by increase in p21 levels and decrease
in cyclin D1 levels.The instability of β-catenin caused by increase of
p-β-catenin expression contributes to CD44-mediated
inhibition of proliferation
Β-catenin is the central effector molecule of the canonical
Wnt signaling pathway, whose deregulation occurs in vari-
ous malignancies including myeloid leukaemias. So we
next sought to investigate whether β-catenin participated
in CD44-mediated tumor cell proliferation. A decreased
mRNA synthesis was observed when CD44 expressions in
K562 cells were silenced (Figure 5A). But the results of
western blotting showed the expressions of β-catenin in
CD44 silencing K562 cells marginally decreased, especially
in CD44 shRNA1 transfecting K562 cells which β-catenin
expression almost did not decrease (Figure 5B). We all
know that the stability destruction of cytoplasmic β-
catenin plays a key role in the signaling output of the
canonical Wnt cascade. So we examined the phosphoryl-
ation level of β-catenin. As our expectation, CD44 shRNA
treatment to K562 cells caused distinguished increased ex-
pression of phosphorylated β-catenin (Figure 5B). Β-
catenin phosphorylation creates a binding site for the E3
ubiquitin ligase, leading to β-catenin ubiquitination and
degradation. Then the nuclear accumulation of β-catenin
was determined by immunofluorescence test. The results
showed that the nuclear accumulation of β-catenin in
CD44 silencing K562 cells dramatically decreased com-
pare to the parental K562 cells, and this outcome was in
accord with the phenomenon that the whole protein ex-
pression of β-catenin significantly decreased (Figure 5C).
These data suggest that β-catenin participated in CD44
mediated cell proliferation mainly though the augmented
phosphorylation level of β-catenin decreased its nuclear
accumulation.Decreased nuclear accumulation of β-catenin caused by
CD44 down-regulation inhibits colony-formation in vitro
To investigate whether CD44-mediated decreased β-
catenin expression affected the clonal proliferation ability
of K562 cells, we compared the in vitro growth character-
istics by means of colony-formation assays. The previous
results showed that transfectants of CD44 shRNA had de-
creased potential of proliferation, of which the β-catenin
protein was accumulated in cytoplasm. In colony-forming
assay, CD44 silencing K562 cells formed less colonies than
the parental cells (Figure 6A and B). And also, the sizes of
colonies formed by CD44 knockdown K562 cells were
smaller than the control (Figure 6A and C). These data
suggested that the inhibition of CD44 impaired the growth
potential of tumor cells compared to wild type or control.CD44 down-regulation inhibits the oncogenic potential of
K562 cells in vivo
We next examined whether down-regulation of CD44 al-
tered the tumorigenic capacity of K562 cells in vivo. When
cells were inoculated subcutaneously, tumors formed in
the CD44shRNA group were consistently smaller in size
than those in the control group. At the end, the total mass
of the tumors harvested from the scramble group was
nearly threefold more than that of the CD44shRNA group
(P < 0.05) (Figure 7A-B). In addition to a small in tumor
size, CD44 knockdown K562 cells showed a significant re-
duction in tumor outgrowth after subcutaneous injection
when compared with control K562 cells (Figure 7C). Fur-
thermore, the scramble transfectants appeared to be more
aggressive, invading into many abdominal organs, such as
spleen, liver and kidney than K562 cells with CD44shRNA
(data was not shown). Collectively, our present findings
strongly suggest that the down-regulation of CD44 signifi-
cantly decreases the tumorigenic capacity of K562 cells
in vivo.
Discussion
Chronic myeloid leukemia (CML) is a clonal myeloprolif-
erative disorder that is characterized by a t (9; 22) trans-
location, which results in the expression of BCR-ABL
fusion oncoproteins that are unique to the leukemic cells.
This fusion oncoprotein is responsible for the increased
activation of several downstream signaling pathways,
which affect malignant cells’ behaviors and are necessary
for oncogenesis and potential immunogenic [17,18]. The
BCR-ABL tyrosine kinase inhibitor imatinib is effective as
a single agent for the treatment of patients in all stages of
CML, with the most encouraging results seen in patients
in chronic phase (CP) disease. Hematologic and cytogen-
etic responses to imatinib for the treatment of CP CML
have permitted imatinib to be registered as first-line treat-
ment for newly diagnosed CML [19,20]. Despite the suc-
cess of imatinib and other tyrosine kinase inhibitors
(TKIs), CML remains largely incurable, and this is likely
due to the treatment resistance of leukemic stem cells,
which are responsible for rapid disease relapse after the
discontinuation of therapy [21,22]. How to treat CML pa-
tients who are resistant to BCR-ABL tyrosine kinase in-
hibitors is an important and urgent issue for clinical
hematology. So making further efforts to understand the
molecular signals in CML is indispensable.
A number of studies have aimed at identifying the spe-
cific molecules expressed in CML stem cells that correl-
ate with oncogenic behaviors. Among such candidates
there is a major cell surface receptor CD44, which is a
multifunctional transmembrane glycoprotein expressed
in many cells and tissues [23]. CD44 is often expressed
as a variety of variant isoforms generated by an alterna-
tive splicing mechanism and the expression of certain
Figure 5 CD44 suppression inhibited nuclear translocation of β-catenin. (A) Decreased β-catenin mRNA expression after CD44shRNA transfec-
tion. (B) The protein expressions of β-catenin and p-β-catenin. (C/D) The relative protein expression of β-catenin and p-β-catenin compared to GAPDH.
*, P < 0.05, **, P < 0.01, compared with the control. (E) Confocal laser microscope showing the decreased nuclear translocation of β-catenin after
treatment with CD44shRNA. The green panel is GFP; the red panel isβ-catenin and the blue panel is cell nuclear.
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Figure 6 Effect of decreased expression of CD44 on cell proliferation in vitro. Colony-forming potential was analyzed by semisolid methylcellu-
lose medium. (A) Representative photographs of colony formation for K562 cells transfected with CD44shRNA or control vector, respectively. Upper
panel (40×) showed the number of colonies, and lower panel (100×) showed the size of colonies. (B) Colony numbers for different K562 cell lines of
each sight under microscope were shown. (C) Colony radius under microscope was also shown. *, P < 0.05, **, P < 0.01, compared with the control.
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known to be associated with many physiological and
pathological processes [24]. So we detected the expressions
of CD44 in leukemic patients and the results showed that
the expressions of CD44 in leukemic patients were higher
than that in normal control. We also examined the CD44
level K562 chronic myeloid leukemia cells compared with
the healthy control and the results were the same with that
in patients’ samples. Liqing et al. also found that CD44 was
a key regulator of AML LSCs to maintain their stem cell
properties and may provide a therapeutic strategy to elim-
inate quiescent AML LSCs [25].
A growing body of literatures implicate that many sig-
naling pathways including Wnt, Hedgehog, Notch and
Bmi which regulate normal stem cell developmentare,
are also classically associated with cancers. One particu-
lar interesting pathway that has also been shown to
regulate both self-renewal of stem cell and oncogenesis
in different organs is the Wnt/β-catenin signaling path-
way [26-29]. And we detected the expression of β-
catenin in K562 after treatment with CD44shRNA. The
results showed that inhibition of CD44 induced slightly
decreased β-catenin level but dramatically increased the
expression of p-β-catenin.The relation between β-catenin and CD44 has been
studied in many solid tumors such as breast cancer,
prostate cancer and colon carcinoma. Sarkar et al.
found the prograstrin could up-regulate the expressions
of β-catenin and CD44, and subsequently increase the
proliferation in vivo [30]. From that study a relatively
good correlation between CD44 and β-catenin expression
pattern could be seen. The study of Han et al. suggested
that siRNA-mediated down-regulation of β-catenin ele-
vated the E-cadherin expression but reduced the CD44 ex-
pressions, which inhibited the invasion and migration of
colon cancer cells [31]. Meanwhile, Wielenga et al. found
the expressions of CD44 family were overexpressed in the
colorectal adenoma carcinoma, which may be regulated
by β-catenin/Tcf-4 signaling pathway [32]. But in leukemia
genesis the relationship between CD44 and β-catenin was
little studied. A report from Bjorklund et al. suggested
that CD44 played an important role in cell adhesion and
resistance to lenalidomide in multiple myeloma, which
could be mediated by β-catenin [33]. In our study, we
found in the CD44 silencing K562 cells the expressions of
β-catenin were down-regulated. These different results
may be form different cell functions in different cell lines.
K562 cell lines are BCR-ABL positive cells, which
Figure 7 Down-regulated expression of CD44 impacted cell proliferation in vivo. (A) Representative pictures of tumor taken at the time of
killing were shown. (B) Volume of subcutaneously formed tumors. Tumor volume was calculated asπLW2/6 for 30 days. (C) subcutaneous tumor
outgrowth of CD44 shRNA and scramble vector-expressing K562 cells. The experiment was carried out blinded and repeated twice with similar
results. Data shown were averages from five mice in each group and were presented as Mean ± SD. *, P < 0.05 by Student’s t-test.
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β-catenin and CD44 may play different functions in these
cells. Krause et al. found that CD44 was indispensable for
induction of leukemia by BCR-ABL and was specifically
required for leukemia stem cell that initiated CML [9].
And a study of Hu et al. suggested that β-catenin played
an essential role on survival and drug-resistance of
leukemia stem cell in mice with BCR-ABL-induced
chronic myeloid leukemia [6]. Meanwhile, accumulated
evidence showed that there is a deregulation and cross talk
among Wnt and other signaling pathway such as Notch in
chronic myeloid leukemia [34]. So, CD44 may have a cross
talk with β-catenin through BCR-ABL and there may be a
regulated loop between CD44 and β-catenin.
To ensure the effects of CD44 on proliferation, we
down-regulated the CD44 level by shRNA and found that
the proliferation of K562 cells significantly decreased com-
pared with that of the parental cells. The inhibition of pro-
liferation was major from the CD44 down-regulation
induced a G0/G1 arrest in cell cycle of K562 cells. These
data indicate that the effects of CD44 on cell proliferation
are partially contributable to the G0/G1 arrest of cell cycle
in K562 cells. Cell cycle progression through G1 to S and
the G2 to M transitions are major checkpoints in the
control of cells’ proliferation. Cyclins, cyclin-dependent
kianses(CDK), and cyclin-dependent kinase inhibitors
(CDKIs) play important roles in the above processes[35-37]. Among these regulators, Cyclin D1 is indispens-
able in regulating the G1 checkpoint. The expression of
Cyclin D1 was usually over-expressed in some kinds of
tumor cells such as the invasive breast cancer and ductal
carcinoma [38]. On the other hand, these kinase activities
of Cyclin/CDK are negatively mediated by CDKIs families
such p21 [39]. But the relationship between Cyclin D1
and p21 was not simply negative. Ashrafi et al. found
that in the breast cancer of wistar albino female rats,
the expressions of Cyclin D1 and p21 were all highky
up-regulated [38]. In our study, we found the down-
regulation of CD44 induced the decreased Cyclin D1 ex-
pression and increased p21 expression. Sengupta et al.
found that β-catenin, CyclinD1, HoxA10 and p21 play im-
portant role in the signaling network for the apparently di-
verse but mutually interconnected self-renewal-associated
genetic programs of CML cells and this finding was con-
sistent with our results [34].
Conclusion
Taken together, in our study we investigate the direct
regulating correlation between CD44 and β-catenin in
K562 cells. These data demonstrate that down-regulation
of CD44 greatly decreases the proliferation by a G0/G1 ar-
rest of cell cycle in K562 cells. And in the process of
CD44-mediated cell proliferation, β-catenin is a target of
CD44 to regulate the expression of p21 and cyclin D1.
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eously targeting to CD44 and β-catenin may be novel
therapeutic strategies for treating CML.
Methods
Cell culture and material
We collected born marrow samples of patients in Hospital
of Blood Diseases. We chose 4 acute myeloid leukaemia
(AML) patients, 4 chronic myeloid leukemia (CML) pa-
tients, 4 acute lymphoblastic leukemia (ALL) patients, 3
myeloproliferative neoplasm (MPN) patients, 3 polycy-
themia vera (PV) patients, 2 essential thrombocythemia
(ET) patients and 2 healthy volunteers. All patients are
newly diagnosed. In all CML patients, three patients were
in chronic phase and one patient was in accelerated phase.
And all AML patients were diagnosed as AML-M3. Inclu-
sion criteria for our study were based on the European
Leukemia Net (ELN) criteria. Clinical evaluation of patients
was performed with physical examination and laboratory
monitoring. All the patient samples were treated in accord-
ance with the Helsinki Declaration. Before the start of
treatment, each patient gave written informed consent.
K562 cells were grown in RPMI 1640 (Gibco-BRL Life
Technologies, Inc. Burlington, ON, Canada) supplemented
with 10% fetal bovine serum (HyClone, Logan, UT),
100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C
in a humid atmosphere with 5% CO2.
RNA interference studies, real-time quantitative PCR and
Western blotting
These analyses were performed as described previously
[40]. Trizol kit (Invitrogen, Grand Island, NY) was used
to isolate total RNA and the concentration of total RNA
was measured by spectrophotometer. Real-time quanti-
tative PCR (see Table 1 for primers) was performed with
ABI 7500 system Instrument with SYBR Green PCR kit
(Takara, Japan).
The total proteins of K562 cells were extracted and
separated by SDS-PAGE. And the protein bands were
detected using ECL Western blotting detection kit (GE
healthcare, UK). For western blotting analysis, we pur-
chased antibodies GAPDH from Santa Cruz Biotech-
nology (Santa Cruz, CA); Cyclin D1, p21, Bcl-xl from
Cell Signaling Technology (Cell Signaling Technology,






β-catenin 5′-CATCATCGTGAGGGCTTACTGCell proliferation assay
To assess the proliferation state of K562 cells after vari-
ous treatments, MTT proliferation assay was performed
according to the manufacturer’s instructions. Briefly,
K562 cells were seed in 96-well plates at a density of 4 ×
104 cells/ml for 1–3 days. A volume of 20 μl MTT label-
ing reagent (5 mg/ml) was added every day to each well
and the plates were incubated at 37°C for 4 h. The
resulting formazon crystals were solubilized by adding
100 ml of solubilization buffer (10% SDS in 0.01 m HCl)
per well and the plates were incubated at 37°C overnight.
The absorbance of the formazon measured at 575 nm
was used to account for the proliferation state of cells.
Trypan blue cell exclusion was also used to assess the
cell viability and the cell number.
Flow cytometry
K562 cell surface staining, cell cycle, and apoptosis ana-
lysis was performed by flow cytometry with a BD LSRII
flow cytometer.
For cell surface staining analysis, K562 Cells were pre-
incubated with CD44 primary antibody for 1 h at 4°C.
After three washes, the K562 cells were incubated with
cy5-conjugated Goat Anti-Mouse IgG secondary anti-
body at room temperature. After analysis, the experi-
ment was analyzed with software of Flowjo 7.6.
For cell cycle analysis, K562 cells in exponential
growth phase were permeated with 75% ethanol for
overnight at 4°C and stained with Propidium Iodide (PI)
in the presence of 5 μg/ml RNase (Sigma) for 10 min.
And cell cycle distribution (G0-G1, S and G2-M) was
analyzed with DNA cell cycle analysis software (ModFit,
Becton Dickinson).
Apoptosis was measured with a commercial kit (Tianjin
Sungene Biotech, China) as recommended by the manu-
facturer. Approximately, 105 K562 cells were stained for
15 minutes with Annexin V- allophycocyanin (APC) and
PI at room temperature in the dark. After analysis, the
apoptotic K562 cells were analyzed with software of
Flowjo 7.6.
Methylcellulose colony formation assays
K562 cells were harvested and washed three times with
IMDM. The cell suspension (2 × 103 cells/ml) were cul-
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10% FBS. Cells were incubated at 37°C with 5% CO2,
and the total number of colonies was counted after
10 days by use of an inverted microscope.
Immunofluorescence assay
K562 cells were fixed with 4% paraformaldehyde for
30 min. K562 Cells were washed with ice-cold PBS,
blocked with 0.5% BSA in PBS for 30 minutes and then
pre-incubated with CD44 primary antibody overnight at
4°C. After three washes, the K562 cells were incubated
with cy3-conjugated AffiniPure Goat Anti-Mouse IgG
secondary antibody at room temperature and stained
nuclei with 1 μg/μl DAPI. Then K562 cells were washed
twice by PBS and the images were visualized with Bio-
Rad 1024 confocal laser microscope.
Inoculation of nude mice
All animal experiments were performed in compliance
with the guidelines of Laboratory Animal Care of National
Institutes of Health for the care and use of laboratory ani-
mals. CD44 shRNA stable transfectants and its parental
K562 cells were tested for their tumorigenic potential
in vivo using nude mice. Five 4-week-old male BALB/C-
nu/nu mice were included in each group. In subcutaneous
models, 3 × 106 cells suspended in 0.1 ml PBS were
injected into the right flank of each mouse at a single site.
Tumor length and width were measured every week after
injection. Volume was calculated as πLW2/6. All mice
were kept in aseptic cages and killed 4 weeks after inocu-
lation by cervical dislocation.
Statistical analysis
Each experiment was repeated at least three times. All
data were summarized and represented as mean ± SD.
The difference between means was statistically ana-
lyzed using the t-test. All statistical analyses were per-
formed using GraphPad Prism software (San Diego, USA).
p < 0.05 was considered as statistically significant.
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